SPOTLIGHT REVIEW Interferon-a therapy in bcr-abl-negative myeloproliferative neoplasms
暂无分享,去创建一个
[1] F. Girodon,et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy , 2008, Haematologica.
[2] S. Chevret,et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.
[3] P. Johansson,et al. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia , 2008, Haematologica.
[4] Renee F Wilson,et al. Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease , 2008, Annals of Internal Medicine.
[5] R. Mesa,et al. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea , 2008, American journal of hematology.
[6] A. Pardanani. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.
[7] H. Kantarjian,et al. PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders , 2007 .
[8] A. Tefferi,et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation , 2007, British journal of haematology.
[9] S. Pestka. The Interferons: 50 Years after Their Discovery, There Is Much More to Learn* , 2007, Journal of Biological Chemistry.
[10] Paul J. Hertzog,et al. Type I Interferon Receptors: Biochemistry and Biological Functions* , 2007, Journal of Biological Chemistry.
[11] T. Barbui,et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden , 2007, Leukemia.
[12] T. Barbui,et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. , 2007, Experimental hematology.
[13] A. Tefferi,et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients , 2007, Leukemia.
[14] J. Jelinek,et al. Polycythemia vera is not initiated by JAK2V617F mutation. , 2007, Experimental hematology.
[15] M. Cazzola,et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders , 2006, Cancer.
[16] G. Massonnet,et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. , 2006, Blood.
[17] H. Deeg,et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.
[18] R. Kralovics,et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. , 2006, Blood.
[19] R. Silver. Long‐term effects of the treatment of polycythemia vera with recombinant interferon‐α , 2006 .
[20] P. Fenaux,et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. , 2006, Seminars in thrombosis and hemostasis.
[21] O. Linder,et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. , 2006, Cancer.
[22] P. Fenaux,et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders , 2006, Leukemia.
[23] M. Griesshammer,et al. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. , 2006, Seminars in thrombosis and hemostasis.
[24] M. Cazzola,et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.
[25] P. Campbell,et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.
[26] M. Griesshammer,et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). , 2005, Blood.
[27] P. Campbell,et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis , 2005, British journal of haematology.
[28] S. Pestka,et al. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. , 2005, Pharmacology & therapeutics.
[29] C. Harrison. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases , 2005, British journal of haematology.
[30] T. Barbui,et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. , 2005, Experimental hematology.
[31] T. Barbui,et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. , 2005 .
[32] S. Sacchi,et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera , 1994, Annals of Hematology.
[33] Y. Nishizawa,et al. Possible selective effects of Interferon α-2b on a malignant clone in a case of polycythemia vera , 1993, Annals of Hematology.
[34] S. Sacchi,et al. Interferon alpha-2b in the long-term treatment of essential thrombocythemia , 1991, Annals of Hematology.
[35] M. Griesshammer,et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. , 2005, Haematologica.
[36] C. D. Krause,et al. Interferons, interferon‐like cytokines, and their receptors , 2004, Immunological reviews.
[37] M. Cazzola,et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.
[38] R. Silver,et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study , 2004, Leukemia.
[39] T. Barbui,et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. , 2004, Haematologica.
[40] J. Kirkwood,et al. Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487) , 2003 .
[41] J. Jelinek,et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. , 2003, Blood.
[42] M. Requena,et al. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon‐α , 2003, American journal of hematology.
[43] Robin M. Hochstrasser,et al. Seeing the Light , 2002, Molecular & Cellular Proteomics.
[44] Z. Estrov,et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia , 2002, Cancer Chemotherapy and Pharmacology.
[45] A. Dispenzieri,et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. , 2001, Blood.
[46] A. Chott,et al. Ineffectiveness of interferon-γ in the treatment of idiopathic myelofibrosis: a pilot study , 2001, Annals of Hematology.
[47] Samir K. Gupta,et al. Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data , 2000 .
[48] Y. Miyakawa,et al. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. , 2000, Blood.
[49] R. Hehlmann,et al. Interferon α in the treatment of polycythemia vera , 2000, Annals of Hematology.
[50] J. Sprent,et al. Stimulation of naive and memory T cells by cytokines , 1999, Immunological reviews.
[51] H. Gisslinger,et al. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera , 1999, European journal of haematology.
[52] H. Gilbert. Long term treatment of myeloproliferative disease with interferon‐α‐2b , 1998 .
[53] C. Clerici,et al. Long‐term therapeutic efficacy and toxicity of recombinant interferon‐alpha 2a in polycythaemia vera , 1998 .
[54] S. Sacchi,et al. Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone , 1998, Leukemia.
[55] E. Wattel,et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. , 1998, Blood.
[56] C. Clerici,et al. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. , 1997, European journal of haematology.
[57] A. Venditti,et al. Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera. , 1998, The American journal of the medical sciences.
[58] Y. Najean,et al. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. , 1997, Blood.
[59] C. Clerici,et al. Polycythemia vera treated with recombinant interferon‐alpha 2a: Evidence of a selective effect on the malignant clone , 1997, American journal of hematology.
[60] Y. Najean,et al. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. , 1997, Blood.
[61] J. Laszlo,et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.
[62] L. Cavanna,et al. Low-dose interferon alpha treatment in essential thrombocythemia. , 2009, European journal of haematology.
[63] M. Griesshammer,et al. Interferon-alpha in the treatment of essential thrombocythemia. , 1996, Leukemia & lymphoma.
[64] J. Reilly,et al. Efficacy of recombinant interferon‐alpha (rIFN‐α) in polycythaemia vera: a study of 17 patients and an analysis of published data , 1996, British journal of haematology.
[65] G. Martinelli,et al. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. , 1996, Haematologica.
[66] Philip R. Cohen,et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] E. Vellenga,et al. Long‐term treatment with interferon‐α2b for severe pruritus in patients with polycythaemia vera , 1995 .
[68] E. Bramanti,et al. Recombinant α2a interferon and polycythemia vera: Clinical results and biological evaluation by means of Fourier‐transform infrared microspectroscopy , 1994, European journal of haematology.
[69] I. Pannacciulli,et al. The in vitro and in vivo effect of recombinant interferon α‐2a on circulating haemopoietic progenitors in polycythaemia vera , 1994, British journal of haematology.
[70] S. Sacchi,et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon‐alpha , 1994, British journal of haematology.
[71] F. Ferrara,et al. Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. , 1994, Acta haematologica.
[72] F. Ferrara,et al. Recombinant interferon α‐2b in the treatment of polycythemia vera , 1993, American journal of hematology.
[73] C. Finelli,et al. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa , 1993, American journal of hematology.
[74] S. Seeber,et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. , 1992, Clinical immunology and immunopathology.
[75] H. Kasparu,et al. Remission may continue after termination of rIFNα ‐2b treatment for essential thrombocythemia , 1992 .
[76] J. San Miguel,et al. alpha Interferon in the management of essential thrombocythaemia. , 1991, European journal of cancer.
[77] C. Schmid,et al. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b. , 1991, European journal of cancer.
[78] W. Scheithauer,et al. Interferon in essential thrombocythaemia , 1991, British journal of haematology.
[79] F. Di Raimondo,et al. Recombinant interferon alpha in the treatment of polycythemia vera. , 1991, Blood.
[80] D. Turri,et al. Alpha-interferon in polycythemia vera and essential thrombocythemia. , 1991, Haematologica.
[81] T. Pearson,et al. Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha‐interferon , 1990, British journal of haematology.
[82] A. Chott,et al. Interferon‐alpha‐induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis , 1990, British journal of haematology.
[83] F. Mandelli,et al. Interferon alpha‐2b as treatment for Philadelphia‐negative chronic myeloproliferative disorders with excessive thrombocytosis , 1989, British journal of haematology.
[84] A. Guarini,et al. In vivo and in vitro inhibitory effect of α‐interferon on megakaryocyte colony growth in essential thrombocythaemia , 1989, British journal of haematology.
[85] J. Harousseau,et al. TREATMENT OF ESSENTIAL THROMBOCYTHAEMIA BY ALPHA 2a INTERFERON , 1988, The Lancet.
[86] R. Silver. RECOMBINANT INTERFERON-ALPHA FOR TREATMENT OF POLYCYTHAEMIA VERA , 1988, The Lancet.
[87] A. Mehta,et al. ALPHA-INTERFERON THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA , 1988, The Lancet.
[88] M. Cazzola,et al. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. , 1987, Blood.
[89] S. Pestka,et al. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. , 1987, Science.
[90] S. Pestka,et al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. , 1983, The Journal of biological chemistry.
[91] K. Cantell,et al. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. , 1981, Methods in enzymology.
[92] S. Pestka,et al. Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[93] G. Volckaert,et al. Isolation and structure of a human fibroblast interferon gene , 1980, Nature.
[94] K. Cantell,et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity , 1980, Nature.
[95] J. Lindenmann,et al. Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.